ArticleThe Journal of clinical investigation2011
FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.
Article in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 130 citations in OpenAlex.
- Tumor Microenvironment-Responsive Nanoparticles for Pancreatic Cancer Imaging and Treatment.International journal of nanomedicine · 2026Review
- TMED3 promotes prostate cancer via FOXO1a and FOXO3a phosphorylation.Oncology research · 2025Article
- Innate immune response restarts adaptive immune response in tumors.Frontiers in immunology · 2023Review
- Tumour Derived Extracellular Vesicles: Challenging Target to Blunt Tumour Immune Evasion.Cancers · 2022Review
- An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.Methods in molecular biology (Clifton, N.J.) · 2020Review
- STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.Frontiers in immunology · 2020Article
- The role of the immune system in brain metastasis.Current neurobiology · 2019Article
- Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma.Cancer immunology, immunotherapy : CII · 2019Article
- WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.Frontiers in immunology · 2019Review
- Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors.Scientific reports · 2017Article
- Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.Advances in experimental medicine and biology · 2017Review
- Didymin reverses phthalate ester-associated breast cancer aggravation in the breast cancer tumor microenvironment.Oncology letters · 2016Article
- FOXO3 rs12212067: T > G Association with Active Tuberculosis in Han Chinese Population.Inflammation · 2016Article
- Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.Translational research : the journal of laboratory and clinical medicine · 2016Review
- MicroRNA-Regulated Proinflammatory Cytokines in Sarcopenia.Mediators of inflammation · 2016Review
- Review
- Summary of the 2014 Alcohol and Immunology Research Interest Group (AIRIG) meeting.Alcohol (Fayetteville, N.Y.) · 2015Article
- Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.Cancer immunology research · 2015Article
- Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.Journal of the National Cancer Institute · 2015Article
- Challenges and future perspectives of T cell immunotherapy in cancer.Immunology letters · 2015Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2015-05-01Falsification/Fabrication of Data · Investigation by Company/Institution · Misconduct - Official Investigation(s) and/or Finding(s) · · Stephanie Watkins responsible; JME 06/27/2017
- Commented on by
- Commented on by
- Retracted
Authors and funding
9 authors at 6 institutions in 5 countries.
Funding
Abstract
The limited success of cancer immunotherapy is often attributed to the loss of antigen-specific T cell function in situ. However, the mechanism for this loss of function is unknown. In this study, we describe a population of tumor-associated DCs (TADCs) in both human and mouse prostate cancer that tolerizes and induces suppressive activity in tumor-specific T cells. In tumors from human prostate cancer patients and transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, TADCs expressed elevated levels of FOXO3 and Foxo3, respectively, which correlated with expression of suppressive genes that negatively regulate T cell function. Silencing FOXO3 and Foxo3 with siRNAs abrogated the ability of human and mouse TADCs, respectively, to tolerize and induce suppressive activity by T cells. Silencing Foxo3 in mouse TADCs was also associated with diminished expression of tolerogenic mediators, such as indoleamine-2,3-dioxygenase, arginase, and TGF-β, and upregulated expression of costimulatory molecules and proinflammatory cytokines. Importantly, transfer of tumor-specific CD4+ Th cells into TRAMP mice abrogated TADC tolerogenicity, which was associated with reduced Foxo3 expression. These findings demonstrate that FOXO3 may play a critical role in mediating TADC-induced immune suppression. Moreover, our results identify what we believe to be a novel target for preventing CTL tolerance and enhancing immune responses to cancer by modulating the immunosuppressive activity of TADCs found in the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.